A $7.5M Oncology Bet, But the Tape Runs Hot

ISB Research · Interesting · sent to Ultimate members August 17, 2026

Chen Hung-Wen runs Apollomics, and he just put $7,550,004 into his own clinical-stage cancer company. That's real money at risk from the one person who knows the trial data before anyone else, and it isn't his first check here either. The trend backs him, all three timeframes point up and the 8-day just crossed above the 20-day, so the algorithms are joining the party. Only catch is price has already run to $23.55 with the MFI pinned near 94 and RSI at 68, so you're chasing a stock that's stretched well above where the CEO bought. Let this one cool toward the 8-day before you follow him in.

Ultimate members received this analysis in real time.